Is Biogen the most desperate buyer scouting the biotech market?
There are several big players in biotech who would clearly love to make a splashy acquisition. A rich Gilead ($GILD), now that the bloom is coming off its hep C rose, is one. AbbVie ($ABBV), because its last big exciting acquisition – Stemcentrx – immediately lost luster at ASCO. Allergan ($AGN) has the money and a dealmaking CEO who likes to think big.
And Pfizer ($PFE) makes the list, because, well, you name it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.